• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

1.83 EUR

-1.30 %

2,224 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-1.30 %
+1.44 %
+4.16 %
-22.54 %
-26.59 %
-44.10 %
-54.30 %
-
-63.87 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
68.34M EUR
Turnover
47.48K EUR
P/E (adj.) (26e)
-7.38
EV/EBIT (adj.) (26e)
-7.63
P/B (26e)
4.56
EV/S (26e)
13.63
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
From the 3:22 mark onwards, Jukka mentions that Ibex had been in use at Institut Curie for free. They then switched to the paid Aiforia service.
7/4/2026, 2:47 PM
by Jekkku
30
TJ Tenkanen has been shopping again on Friday; the previous trades were made a week earlier. I’m starting to give some weight to these voluntary management acquisitions; with experience, it’s beginning to become a red flag for me if this doesn’t happen (Sosi, Optomed, BBS…). HOWEVER...
11 hours ago
by Akkanen
14
If I had to guess, Lundin probably already has his next startup in the works. It’s likely a good idea to set aside capital for it now that Aiforia is up and running. It’s worth watching the video linked here earlier, which features a lecture by Lundin on the subject. He talks specifically...
9 hours ago
by jerej
10
aiforia.com Join Aiforia's partner network Aiforia’s network of partners ensures that our customers in clinical, pre-clinical, and academic labs can choose the technologies and enjoy the full benefits of a digitized workflow with seamless integrations into their existing laboratory...
yesterday
by Salvelinus
9
I also noticed in Anne’s presentation that the slideshow dates end in October 2025. Aiforia won the Institut Curie account in October 2025. It seems that Anne was brought in as a shareholder/employee to give a presentation as an expert for Ibex at the trade fair in question.
7/4/2026, 2:33 PM
by Jekkku
9
Could that first batch sold by Lundin have gone to Tenkanen? The quantity and price are at least the same.
10 hours ago
by Salvelinus
7
Indeed, insider purchases are quite often a positive signal from the perspective of a company’s success. Regarding Lundin, the sale and the reasons behind it are more difficult to interpret. Perhaps he has other commitments and financial needs. His main job is in the academic world...
10 hours ago
by veronmaksaja
6
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.8
2026

Interim report Q2'26

Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies
Regulatory press release01.07.2026, 20.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research29.06.2026, 09.21

Aiforia Technologies: € 6.4m share issue de-risks the investment case - NuWays AG Research

On Thursday evening, Aiforia announced having completed a directed share issue of 3.6m shares at € 1.772 per share, raising gross proceeds of some € 6.4m. The subscription price corresponds to the closing price of June 25th, representing no discount ...

Aiforia Technologies
Regulatory press release26.06.2026, 15.30

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release26.06.2026, 15.20

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Tuomas Tenkanen/TJT Technologies Oy)

Aiforia Technologies
Regulatory press release26.06.2026, 11.15

A total of 3,600,000 new shares in Aiforia Technologies Plc registered with the Trade Register

Aiforia Technologies
Aiforia collects 6.4 MEUR in a directed share issue
Analyst Comment26.06.2026, 07.49 by
Antti Siltanen

Aiforia collects 6.4 MEUR in a directed share issue

The company's financial risk in the coming years will diminish if the planned EIB loan materializes in addition to the share issue.

Aiforia Technologies
Regulatory press release25.06.2026, 21.00

Inside information: Aiforia Technologies Plc successfully completes a directed share issue raising approximately EUR 6.4 million

Aiforia Technologies
Regulatory press release25.06.2026, 17.31

Inside information: Aiforia Technologies Plc intends to carry out a directed share issue by means of an accelerated bookbuilding process

Aiforia Technologies
Third party research17.06.2026, 08.21

Aiforia Technologies: €20m EIB debt term sheet de-risks Aiforia's funding outlook - NuWays AG Research

Aiforia agrees non-binding EIB term sheet for up to €20m venture debt, materially de-risking the funding outlook. BUY, PT €3.80 unchanged.

Aiforia Technologies
Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB
Analyst Comment16.06.2026, 08.16 by
Antti Siltanen, Antti Luiro

Aiforia indicatively agreed on a 20 MEUR financing facility with the EIB

The financing package would significantly reduce the short-term financing risk.

Aiforia Technologies
Regulatory press release15.06.2026, 20.45

Inside information: Aiforia and the European Investment Bank agree upon a non-binding indicative term sheet for an up to EUR 20 million venture debt financing facility

Aiforia Technologies
Aiforia expands to nine hospitals in Spain
Analyst Comment12.06.2026, 08.26 by
Antti Siltanen

Aiforia expands to nine hospitals in Spain

The news continues Aiforia's series of gradual growth steps with 9 new hospitals.

Aiforia Technologies
Press release11.06.2026, 08.30

Aiforia expands its presence in Spain through a new clinical account

Aiforia Technologies
Regulatory press release18.05.2026, 16.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act - Mikko Laakkonen’s holding in Aiforia Technologies Plc

Aiforia Technologies
M&A activity in digital pathology is increasing
Analyst Comment15.05.2026, 08.45 by
Antti Siltanen, Antti Luiro

M&A activity in digital pathology is increasing

Consolidation has occurred in Aiforia's industry over the past 12–18 months.

Aiforia Technologies
Regulatory press release12.05.2026, 12.00

Resolutions of Aiforia Technologies Plc’s Extraordinary General Meeting 2026

Aiforia Technologies
Third party research11.05.2026, 09.18

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research (R)

(Link updated) Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection...

Aiforia Technologies
Third party research11.05.2026, 08.12

Aiforia Technologies: Strong cross-read from Roche's PathAI takeover - NuWays AG Research

Last week, Roche announced the acquisition of PathAI for up to $ 1.05bn ($ 750m upfront, $ 300m in earnouts), to be integrated into its Diagnostics division. PathAI is privately held, and few valuation details are provided in connection with the deal...

Aiforia Technologies